-
Je něco špatně v tomto záznamu ?
A.R.R.O.W.2: once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma
MA. Dimopoulos, D. Coriu, S. Delimpasi, I. Špička, T. Upchurch, B. Fang, R. Talpur, E. Faber, M. Beksac, X. Leleu
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, randomizované kontrolované studie, multicentrická studie, klinické zkoušky, fáze III
NLK
Directory of Open Access Journals
od 2016
PubMed Central
od 2016
Europe PubMed Central
od 2016
ROAD: Directory of Open Access Scholarly Resources
od 2016
- MeSH
- dexamethason * aplikace a dávkování terapeutické užití MeSH
- dospělí MeSH
- lenalidomid * aplikace a dávkování terapeutické užití MeSH
- lidé středního věku MeSH
- lidé MeSH
- mnohočetný myelom * farmakoterapie mortalita MeSH
- oligopeptidy * aplikace a dávkování terapeutické užití MeSH
- protokoly protinádorové kombinované chemoterapie * terapeutické užití škodlivé účinky MeSH
- recidiva MeSH
- rozvrh dávkování léků MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze III MeSH
- multicentrická studie MeSH
- randomizované kontrolované studie MeSH
Twice-weekly carfilzomib (27 mg/m2) plus lenalidomide and dexamethasone (KRd27) is a standard of care in relapsed/refractory multiple myeloma (RRMM). Once-weekly carfilzomib regimens have shown clinical benefits with improved patient convenience. This open-label, phase 3, multicenter, randomized study aimed to demonstrate noninferiority of the overall response rate (ORR) for once-weekly carfilzomib (56 mg/m2) plus Rd (KRd56) vs twice-weekly KRd27 in RRMM. A total of 454 patients were randomized (1:1) to receive carfilzomib as once-weekly 30-minute infusions of 56 mg/m2 (KRd56; n = 228) or twice-weekly 10-minute infusions of 27 mg/m2 (KRd27; n = 226). Baseline characteristics were balanced between groups. ORR was 82.5% (95% confidence interval [CI], 76.9-87.2) in the once-weekly group vs 86.3% (95% CI, 81.1-90.5) in the twice-weekly group (risk ratio, 0.954 [95% CI, 0.882-1.032]) and did not meet the threshold for statistical significance of noninferiority (P = .0666). Complete response (CR) or better was obtained in 46.9% of patients in the once-weekly arm and 36.3% in the twice-weekly arm. The proportions of patients who achieved CR and were also assessed negative for minimal residual disease were 21.5% and 18.1%, respectively (odds ratio, 1.235 [95% CI, 0.775-1.970]). Progression-free survival was comparable between groups (hazard ratio, 0.945 [95% CI, 0.617-1.447]). The safety profile was similar for both groups. In conclusion, although statistical significance for noninferiority of ORR was not achieved, the efficacy and safety of once-weekly KRd56 were similar to those of twice-weekly KRd27, and once-weekly KRd56 may be an effective and convenient treatment option for patients with RRMM. This trial was registered at www.ClinicalTrials.gov as #NCT03859427.
Department of Haematology Carol Davila University of Medicine and Pharmacy Bucharest Romania
Department of Hematology and Bone Marrow Transplantation Unit Evangelismos Hospital Athens Greece
Department of Hematology and Cellular Therapy CIC U1402 CHU de Poitiers Poitiers France
Department of Hematology Fundeni Clinical Institute Bucharest Romania
Hematology Ankara Liv Hospital Istinye University Ankara Turkey
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24018717
- 003
- CZ-PrNML
- 005
- 20241024111219.0
- 007
- ta
- 008
- 241015s2024 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1182/bloodadvances.2024013101 $2 doi
- 035 __
- $a (PubMed)39024542
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Dimopoulos, Meletios A $u Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
- 245 10
- $a A.R.R.O.W.2: once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma / $c MA. Dimopoulos, D. Coriu, S. Delimpasi, I. Špička, T. Upchurch, B. Fang, R. Talpur, E. Faber, M. Beksac, X. Leleu
- 520 9_
- $a Twice-weekly carfilzomib (27 mg/m2) plus lenalidomide and dexamethasone (KRd27) is a standard of care in relapsed/refractory multiple myeloma (RRMM). Once-weekly carfilzomib regimens have shown clinical benefits with improved patient convenience. This open-label, phase 3, multicenter, randomized study aimed to demonstrate noninferiority of the overall response rate (ORR) for once-weekly carfilzomib (56 mg/m2) plus Rd (KRd56) vs twice-weekly KRd27 in RRMM. A total of 454 patients were randomized (1:1) to receive carfilzomib as once-weekly 30-minute infusions of 56 mg/m2 (KRd56; n = 228) or twice-weekly 10-minute infusions of 27 mg/m2 (KRd27; n = 226). Baseline characteristics were balanced between groups. ORR was 82.5% (95% confidence interval [CI], 76.9-87.2) in the once-weekly group vs 86.3% (95% CI, 81.1-90.5) in the twice-weekly group (risk ratio, 0.954 [95% CI, 0.882-1.032]) and did not meet the threshold for statistical significance of noninferiority (P = .0666). Complete response (CR) or better was obtained in 46.9% of patients in the once-weekly arm and 36.3% in the twice-weekly arm. The proportions of patients who achieved CR and were also assessed negative for minimal residual disease were 21.5% and 18.1%, respectively (odds ratio, 1.235 [95% CI, 0.775-1.970]). Progression-free survival was comparable between groups (hazard ratio, 0.945 [95% CI, 0.617-1.447]). The safety profile was similar for both groups. In conclusion, although statistical significance for noninferiority of ORR was not achieved, the efficacy and safety of once-weekly KRd56 were similar to those of twice-weekly KRd27, and once-weekly KRd56 may be an effective and convenient treatment option for patients with RRMM. This trial was registered at www.ClinicalTrials.gov as #NCT03859427.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a mnohočetný myelom $x farmakoterapie $x mortalita $7 D009101
- 650 12
- $a dexamethason $x aplikace a dávkování $x terapeutické užití $7 D003907
- 650 12
- $a oligopeptidy $x aplikace a dávkování $x terapeutické užití $7 D009842
- 650 12
- $a lenalidomid $x aplikace a dávkování $x terapeutické užití $7 D000077269
- 650 12
- $a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $x škodlivé účinky $7 D000971
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a rozvrh dávkování léků $7 D004334
- 650 _2
- $a recidiva $7 D012008
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a klinické zkoušky, fáze III $7 D017428
- 700 1_
- $a Coriu, Daniel $u Department of Hematology, Fundeni Clinical Institute, Bucharest, Romania $u Department of Haematology, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania $1 https://orcid.org/0000000272516079
- 700 1_
- $a Delimpasi, Sosana $u Department of Hematology and Bone Marrow Transplantation Unit, Evangelismos Hospital, Athens, Greece $1 https://orcid.org/0000000175237510
- 700 1_
- $a Špička, Ivan $u First Department of Medicine, Department of Hematology, First Faculty of Medicine, Charles University and General Hospital, Prague, Czech Republic $1 https://orcid.org/0000000254515283 $7 jn20001103644
- 700 1_
- $a Upchurch, Terry $u Amgen Inc, Thousand Oaks, CA
- 700 1_
- $a Fang, Belle $u Amgen Inc, Thousand Oaks, CA
- 700 1_
- $a Talpur, Rakhshandra $u Amgen Inc, Thousand Oaks, CA
- 700 1_
- $a Faber, Edward $u Oncology Hematology Care, Inc, Cincinnati, OH
- 700 1_
- $a Beksac, Meral $u Hematology, Ankara Liv Hospital, Istinye University, Ankara, Turkey $1 https://orcid.org/0000000317978657
- 700 1_
- $a Leleu, Xavier $u Department of Hematology and Cellular Therapy, CIC U1402 CHU de Poitiers, Poitiers, France $1 https://orcid.org/0000000298224170
- 773 0_
- $w MED00194912 $t Blood advances $x 2473-9537 $g Roč. 8, č. 19 (2024), s. 5012-5021
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39024542 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241015 $b ABA008
- 991 __
- $a 20241024111213 $b ABA008
- 999 __
- $a ok $b bmc $g 2201529 $s 1230690
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 8 $c 19 $d 5012-5021 $e 20241008 $i 2473-9537 $m Blood advances $n Blood Adv $x MED00194912
- LZP __
- $a Pubmed-20241015